0001645113-21-000062.txt : 20210429 0001645113-21-000062.hdr.sgml : 20210429 20210429060832 ACCESSION NUMBER: 0001645113-21-000062 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210429 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210429 DATE AS OF CHANGE: 20210429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 21866901 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 8-K 1 nvcr-20210429.htm 8-K nvcr-20210429
0001645113false00016451132021-04-262021-04-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

April 29, 2021
Date of Report (date of earliest event reported)

NovoCure Limited
(Exact name of registrant as specified in its charter)
Jersey
001-37565
98-1057807
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street
St. Helier
Jersey
JE2 4UF
(Address of Principal Executive Offices)
(Zip Code)
+44 (0) 15 3475 6700
Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o




Item 2.02     Results of Operations and Financial Condition.

On April 29, 2021, the Company issued a press release announcing certain financial results for the quarter ended
March 31, 2021. A copy of the press release is attached as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited
(Registrant)

Date: April 29, 2021


By: /s/ Ashley Cordova  
Name: Ashley Cordova
Title: Chief Financial Officer

EX-99.1 2 nvcr-20210331xpr2xnew.htm EX-99.1 Document

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $134.7 million with 80% gross margin

Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size

St. Helier, Jersey – Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven by COVID-19, as well as continued progress across the company’s clinical and product development programs. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer cell division.

First quarter 2021 highlights include:

Three Months Ended
March 31,
20212020% Change
Financial, in millions
Net revenues$134,695 $101,828 32 %
Gross Profit$108,310 $77,332 40 %
Net income (loss)$(4,128)$3,952 (204)%
Adjusted EBITDA(1)
$21,145 $15,064 40 %
Non-financial
Active patients at period end(2)
3,454 3,095 12 %
Prescriptions received in period(3)
1,402 1,409 — %

(1) Adjusted EBITDA is a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation.

(2) An “active patient” is a patient who is receiving treatment under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.

(3) A “prescription received” is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients for a patient not previously on Optune or Optune Lua. Orders to renew or extend treatment are not included in this total.

“Over the last several months, we have made progress across multiple clinical development programs intended to determine Tumor Treating Fields’ optimal use,” said William Doyle, Novocure’s Executive Chairman. “We continued to increase our understanding of the potential benefits of Tumor Treating Fields when used together



with immunotherapies and continued to enroll patients in five late-stage clinical trials in multiple solid tumor types. The accelerated interim analysis of the LUNAR trial and the upcoming HEPANOVA data presentation represent the beginning of what we expect to be an exciting few years of data readouts from our pipeline.”

“Our track record of consistent execution and financial strength continued in the first quarter of 2021,” added Asaf Danziger, Novocure’s Chief Executive Officer. “We generated $135 million in net revenues with an 80% gross margin, and we invested $46 million in research and development intended to fuel future growth. With 3,454 active patients on therapy at the end of the quarter, we have treated nearly 20,000 patients globally, to date.”

First quarter 2021 financial update
For the quarter ended March 31, 2021, net revenues were $134.7 million, representing 32% growth compared to the first quarter 2020.

In the United States, net revenues totaled $85.9 million in the quarter ended March 31, 2021, representing 24% growth compared to the same period in 2020.
In Germany and other EMEA markets, net revenues totaled $35.0 million in the quarter ended March 31, 2021, representing 43% growth compared to the same period in 2020.
In Japan, net revenues totaled $8.3 million in the quarter ended March 31, 2021, representing 28% growth compared to the same period in 2020.
In Greater China, net revenues totaled $5.5 million in the quarter ended March 31, 2021, representing 237% growth compared to the same period in 2020.
For the three months ended March 31, 2021, the increase in net revenues from the first quarter of 2020 resulted primarily from an increase of 359 active patients in our currently active markets and a durable improvement in the net revenues booked per active patient.
We recorded $9.4 million in revenues from Medicare fee-for-service beneficiaries billed under the coverage policy effective on September 1, 2019 in the first quarter 2021, an increase of 32% from the $7.1 million recognized in the same period in 2020. We have gained a good understanding of how to ensure timely processing of Medicare claims and we believe that we have sufficient experience to recognize approximately two-thirds of the expected contribution from Medicare beneficiaries. In the first quarter of 2021, incremental net revenues resulting from the successful appeal of previously denied claims for Medicare fee-for-service beneficiaries billed prior to established coverage reverted to normalized levels from the first half of 2020.
Cost of revenues for the three months ended March 31, 2021 was $26.4 million compared to $24.5 million for the same period in 2020, representing an increase of 8%. The increase in cost of revenues was primarily due to the cost of shipping transducer arrays to a higher volume of commercial patients and increasing shipments of



equipment to Zai Lab. Gross margin was 80% for the three months ended March 31, 2021 compared to 76% for the three months ended March 31, 2020.

Research, development and clinical trials expenses for the three months ended March 31, 2021 were $45.9 million compared to $25.3 million for the same period in 2020, representing an increase of 82%. This was primarily due to an increase in clinical trial and personnel expenses for our phase 3 pivotal and post-marketing trials, an increase in development and personnel expenses to support our product development programs, increased investments in preclinical research and the expansion of our medical affairs activities.

Sales and marketing expenses for the three months ended March 31, 2021 were $31.4 million compared to $28.8 million for the same period in 2020, representing an increase of 9%. This was primarily due to an increase in personnel and professional services costs to support our growing commercial business and reimbursement efforts.

General and administrative expenses for the three months ended March 31, 2021 were $31.1 million compared to $26.6 million for the same period in 2020, representing an increase of 17%. This was primarily due to an increase in personnel costs and professional services.

Net loss for the three months ended March 31, 2021 was $4.1 million compared to net income of $4.0 million for the same period in 2020.

At March 31, 2021, we had $864.4 million in cash and cash equivalents and short-term investments, an increase of $21.8 million compared to $842.6 million at December 31, 2020. The increase in our cash, cash equivalents and short-term investments was primarily due to the cash flow from operations and the exercise of options.

First quarter 2021 operating statistics
There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.

In the United States, there were 2,183 active patients at March 31, 2021, representing 8% growth compared to March 31, 2020.
In Germany and other EMEA markets, there were 1,000 active patients at March 31, 2021, representing 18% growth compared to March 31, 2020.
In Japan, there were 271 active patients at March 31, 2021, representing 22% growth compared to March 31, 2020.

Additionally, 1,402 prescriptions were received in the quarter ended March 31, 2021, representing no change compared to the same period in 2020, and a 1% decrease compared to the quarter ended December 31, 2020. We believe the prolonged disruption caused by COVID-19 is resulting in increased volatility across global health care systems, such as fluctuations in patient volumes and changes in patterns of care in certain regions, which had some impact on our business in the first quarter.




In the United States, 917 prescriptions were received in the quarter ended March 31, 2021, representing a 7% decrease compared to the same period in 2020.
In Germany and other EMEA markets, 382 prescriptions were received in the quarter ended March 31, 2021, representing 16% growth compared to the same period in 2020.
In Japan, 103 prescriptions were received in the quarter ended March 31, 2021, representing 10% growth compared to the same period in 2020.


First quarter 2021 non-U.S. GAAP measures
We also measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

Adjusted EBITDA was $21.1 million for the three months ended March 31, 2021, an increase of $6.1 million, or 40%, from $15.1 million for the three months ended March 31, 2020. This improvement in fundamental financial performance was driven by net revenue growth coupled with an ongoing commitment to disciplined management of expenses.

Recent clinical milestones
Earlier this April, we disclosed that an independent data monitoring committee (DMC) informed Novocure that the pre-specified interim analysis for the phase 3 pivotal LUNAR trial for the treatment of non-small cell lung cancer (NSCLC) was accelerated given the length of accrual and the number of events observed, to date. The interim analysis included data from 210 patients accrued through February 2021. After review of the interim analysis, the DMC concluded that the LUNAR trial should continue with no evidence of increased systemic toxicity. The DMC went on to comment that the continued accrual to 534 patients as proposed in the original protocol, given the current rate of accrual and the interim data presented, is likely unnecessary and possibly unethical for patients randomized to control. For this reason, the DMC recommended an adjustment of accrual to approximately 276 patients with a 12-month follow-up following the enrollment of the last patient. The DMC believes this amended protocol would provide adequate data regarding toxicity and efficacy, providing sufficient overall power, as well as potentially providing important information regarding efficacy within treatment subgroups.

In April, we concluded our phase 2 pilot HEPANOVA trial investigating TTFields together with sorafenib, a kinase inhibitor, in 25 patients with advanced liver cancer. We have submitted an abstract for presentation at an upcoming medical conference in late June



and look forward to discussing the full data set with clinicians, investigators and investors in the future.

In April, the U.S. Food and Drug Administration (FDA) approved our investigational device exemption (IDE) application to initiate the KEYNOTE-B36 phase 2 pilot trial to study TTFields with pembrolizumab in first-line NSCLC through our clinical collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). We are currently evaluating clinical trial sites for initiation.

Anticipated clinical milestones
FDA response to IDE supplement incorporating recommended protocol changes to phase 3 pivotal LUNAR trial in NSCLC (Q2 2021)
Presentation of full data from phase 2 pilot HEPANOVA trial in advanced liver cancer (Q2 2021)
Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (Q3 2021)
Data from phase 2 pilot EF-31 trial in gastric cancer (2022)
Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2022)
Data from phase 3 pivotal METIS trial in brain metastases (2022)
Data from phase 2 pilot EF-33 trial with high-intensity arrays in recurrent glioblastoma (2022)
Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2023)
Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2023)
Final data from phase 3 pivotal LUNAR trial in NSCLC (to be determined pending FDA approval of IDE supplement)


Conference call details
Novocure will host a conference call and webcast to discuss first quarter 2021 financial results at 8 a.m. EDT today, Thursday, April 29, 2021. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 2286525.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its



innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer and glioblastoma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 25, 2021 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.



Consolidated Statements of Operations
USD in thousands (except share and per share data)

Three months ended March 31,Year ended December 31,
202120202020
UnauditedAudited
Net revenues$134,695 $101,828 $494,366 
Cost of revenues26,385 24,496 106,501 
Gross profit108,310 77,332 387,865 
Operating costs and expenses:
Research, development and clinical trials45,916 25,271 132,010 
Sales and marketing31,357 28,834 118,017 
General and administrative31,125 26,608 107,437 
Total operating costs and expenses108,398 80,713 357,464 
Operating income (loss)(88)(3,381)30,401 
Financial expenses (income), net2,646 2,432 12,299 
Income (loss) before income tax(2,734)(5,813)18,102 
Income tax1,394 (9,765)(1,706)
Net income (loss)$(4,128)$3,952 $19,808 
Basic net income (loss) per ordinary share$(0.04)$0.04 $0.20 
Weighted average number of ordinary shares used in computing basic net income (loss) per share102,633,545 99,877,567 100,930,866 
Diluted net income (loss) per ordinary share$(0.04)$0.04 $0.18 
Weighted average number of ordinary shares used in computing diluted net income (loss) per share102,633,545 108,100,623 108,877,648 



Consolidated Balance Sheets
USD in thousands (except share data)
March 31,
2021
December 31, 2020
UnauditedAudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$314,547 $234,674 
Short-term investments549,855 607,902 
Restricted cash11,430 11,499 
Trade receivables, net92,514 96,699 
Receivables and prepaid expenses18,922 21,245 
Inventories27,968 27,422 
Total current assets1,015,236 999,441 
LONG-TERM ASSETS:
Property and equipment, net11,733 11,395 
Field equipment, net12,132 11,230 
Right-of-use assets17,741 19,009 
Other long-term assets10,788 10,908 
Total long-term assets52,394 52,542 
TOTAL ASSETS$1,067,630 $1,051,983 



Consolidated Balance Sheets
USD in thousands (except share data)


March 31,
2021
December 31, 2020
UnauditedAudited
The accompanying notes are an integral part of these unaudited consolidated financial statements.
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables$52,703 $53,647 
Other payables, lease liabilities and accrued expenses57,784 59,965 
Total current liabilities110,487 113,612 
LONG-TERM LIABILITIES:
Long-term debt, net559,584 429,905 
Deferred revenue9,577 12,139 
Long-term leases12,708 14,293 
Employee benefits2,963 5,171 
Other long-term liabilities177 337 
Total long-term liabilities585,009 461,845 
TOTAL LIABILITIES695,496 575,457 
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Share capital -
Ordinary shares no par value, unlimited shares authorized; issued and outstanding:
103,187,460 shares and 102,334,276 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively
— — 
Additional paid-in capital1,005,785 1,111,435 
Accumulated other comprehensive income (loss)(1,948)(3,832)
Retained earnings (accumulated deficit)(631,703)(631,077)
TOTAL SHAREHOLDERS' EQUITY372,134 476,526 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$1,067,630 $1,051,983 



Non-U.S. GAAP financial measures reconciliation
USD in thousands

Three months ended March 31,
20212020% Change
Net income (loss)$(4,128)$3,952 (204)%
Add: Income tax1,394 (9,765)(114)%
Add: Financial income (expenses), net2,646 2,432 %
Add: Depreciation and amortization2,370 1,888 26 %
EBITDA$2,282 $(1,493)(253)%
Add: Share-based compensation18,863 16,557 14 %
Adjusted EBITDA$21,145 $15,064 40 %



Investors:
Adam Daney
investorinfo@novocure.com
610-723-7427

Media:
media@novocure.com
610-723-7428

EX-101.SCH 3 nvcr-20210429.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 nvcr-20210429_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 nvcr-20210429_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 nvcr-20210429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Entity Address, Country Entity Address, Country Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 nvcr-20210429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 nvcr-20210429_htm.xml IDEA: XBRL DOCUMENT 0001645113 2021-04-26 2021-04-30 0001645113 false 8-K 2021-04-29 NovoCure Limited Y9 001-37565 98-1057807 No. 4 The Forum, Grenville Street St. Helier JE JE2 4UF 44 (0) 15 3475 6700 false false false false Ordinary Shares, no par value NVCR NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information Document
Apr. 30, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 29, 2021
Entity Registrant Name NovoCure Limited
Entity Central Index Key 0001645113
Amendment Flag false
Entity Incorporation, State or Country Code Y9
Entity File Number 001-37565
Entity Tax Identification Number 98-1057807
Entity Address, Address Line One No. 4 The Forum, Grenville Street
Entity Address, City or Town St. Helier
Entity Address, Country JE
Entity Address, Postal Zip Code JE2 4UF
City Area Code 44 (0) 15
Local Phone Number 3475 6700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, no par value
Trading Symbol NVCR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.novocure.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports nvcr-20210429.htm nvcr-20210331xpr2xnew.htm nvcr-20210429.xsd nvcr-20210429_cal.xml nvcr-20210429_def.xml nvcr-20210429_lab.xml nvcr-20210429_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nvcr-20210429.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "nvcr-20210429_cal.xml" ] }, "definitionLink": { "local": [ "nvcr-20210429_def.xml" ] }, "inline": { "local": [ "nvcr-20210429.htm" ] }, "labelLink": { "local": [ "nvcr-20210429_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nvcr-20210429_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nvcr-20210429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nvcr", "nsuri": "http://www.novocure.com/20210429", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20210429.htm", "contextRef": "i9c7ace17361f4b81a30c344c896d17f6_D20210426-20210430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.novocure.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nvcr-20210429.htm", "contextRef": "i9c7ace17361f4b81a30c344c896d17f6_D20210426-20210430", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.novocure.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001645113-21-000062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001645113-21-000062-xbrl.zip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end